boundlessbio.com - BOLD Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Boundless Bio, Inc. (BOLD) holds exclusive patents in the field of tumor combat, creating a powerful moat against competitors under strict FDA oversight. The technical infrastructure and IT capabilities for genome analysis function flawlessly. The price action based on the EV/EBITDA metric is 0.00. The business focuses on discovering cancer therapy methods; therefore, financial stability and revenues depend directly on the outcomes of scientific research.
Analytical breakdowns for Boundless Bio, Inc.
- current price and projected stock value:
- issuer market value details:
- book value of equity indicators:
- business debt structure and liquidity details:
Debt to Equity Boundless Bio, Inc.|BOLD - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Boundless Bio|BOLD - Aggregate Debt Obligations|Debts to Book Capitalization Boundless Bio Inc|BOLD - Company Long-Term Debt|Company Short-Term Debts Boundless Bio|Quick Liquidity boundlessbio.com
- financial results and valuation multiples details:
BOLD - Company Net Income|Future Profit Boundless Bio, Inc.|BOLD - Company Value to Net Income|Forward P/E Multiple Boundless Bio, Inc.|BOLD - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Boundless Bio Inc|BOLD - Operating profit before amortization|Net earnings per share (EPS TTM) Boundless Bio|BOLD - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months boundlessbio.com|BOLD - Expected net earnings per share growth this year|Earnings growth forecast for next year Boundless Bio, Inc.
Summary company analysis:Boundless Bio, Inc BOLD
This metric reflects the ratio of total enterprise value to operating profit before depreciation and amortization, allowing for an assessment of the asset's real value accounting for debt and market capitalization. By analyzing the Enterprise Value to EBITDA multiple, an investor determines the degree of overvaluation for Boundless Bio, Inc. (BOLD), where the patent monopoly on the Inertia platform in oncology creates a foundation for future high margins and long-term business sustainability.
Who Boundless Bio, Inc. competes with
EV/EBITDA Multiple TEM (tempus.com)|QGEN: Enterprise Value to Operating Income Before Depreciation|IONS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RGEN: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RNA: EV/EBITDA Multiple|Company Value to EBITDA CRISPR Therapeutics Inc (CRSP)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sema4|Ultragenyx Corp (RARE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics Inc. (BEAM)|Total Company Value to Operating Income Before Depreciation Ratio sarepta.com|Twist Bioscience, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TXG|Intellia - EV/EBITDA Multiple|STOK: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BLFS: EV/EBITDA Multiple|WVE - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Maze Therapeutics|Company Value to EBITDA Sionna Therapeutics, Inc. SION|Enterprise Value to EBITDA Ratio PRME (Prime Medicine Corp)|TSHA (Taysha Corp) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple QURE (uniQure N.V.)|Total Company Value to Operating Income Before Depreciation Ratio meiragtx.com (MGTX)|RGNX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SLDB (Solid Biosciences Inc) - Enterprise Value to Operating Income Before Depreciation|OCGN: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio PacBio Corp|Enterprise Value to EBITDA Ratio BNTC|designtx.com (DSGN) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple RCKT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FDMT (4DMT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexeo Therapeutics, Inc. LXEO|Korro Bio Inc. (KRRO) - Company Value to EBITDA|EDIT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SLN: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PRQR: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation CDXS|SGMO (Sangamo) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation NAUT (Nautilus Biotechnology Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Metagenomi, Inc. (MGX)|precisionbiosciences.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple GBIO (Generation Bio)|EV/EBITDA Multiple Exicure Inc. XCUR|Celsion Corporation - EV/EBITDA Multiple|PHIO: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|mustangbio.com (MBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA TransCode Therapeutics, Inc. (RNAZ)|Enterprise Value to EBITDA Ratio BNGO|EV/EBITDA Multiple Applied DNA Sciences Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bluebird Bio (BLUE)|immunoprecise.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple OMGA (Omega Therapeutics)|OMIC: Enterprise Value to Operating Income Before Depreciation|RGLS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SYRS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TBIO: EV/EBITDA Multiple|Company Value to EBITDA TRACON Pharmaceuticals, Inc (TCON)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology
